MEDP - Medpace Corp Total Debt to Capital

Medpace Holdings, Inc. (MEDP) provides global logistics for biosamples with strict temperature control, maintaining a powerful defensive moat due to the complexity of switching partners under FDA standards. The d/e ratio (total debt to equity) helps identify overleverage risks in a timely manner, with the metric currently standing at 0.28. Business scaling relies on digital platforms that enable the efficient management of numerous clinical trials.

MEDP: Medpace Total Debt to Capital 07/04/2022 - 10/31/2026

Analytical breakdowns for Medpace Holdings, Inc.

- price and consensus price forecast:

Price Chart Medpace|MEDP - Forecast Levels Chart

- market capitalization statistics:

Market Capitalization Medpace|MEDP - Value Adjusted for Debt and Cash

- book capitalization indicators:

Book Value per Share Medpace|MEDP - Book Capitalization|Market Value to Book Value Ratio medpace.com|MEDP - Aggregate Asset Value

- company total debt and liquidity indicators:

- earnings and valuation multiples information:

MEDP - Company Net Income

Basic company analysis:Medpace

Investors determine the financial stability of Medpace Holdings, Inc. (MEDP) through an analysis of its debt load. The clinical research outsourcing model utilizing external laboratories minimizes the need for capital expenditures. This debt-to-equity ratio compares the total amount of liabilities against the company's own equity. A low ratio confirms the business's independence from creditors. Such a profile characterizes the asset as conservative and defensive.

Competitor analysis for Medpace Holdings, Inc.